Characterization and translational development of IOA-289, a novel autotaxin inhibitor for the treatment of solid tumors

BACKGROUND: Autotaxin-lysophosphatidic acid (ATX-LPA) signaling has a predominant role in immunological and fibrotic processes, including cancer. Several ATX inhibitors and LPA receptor antagonists have been clinically evaluated, but none in patients with solid tumors. Many cancers are burdened with...

Descripción completa

Detalles Bibliográficos
Autores principales: Deken, M.A., Niewola-Staszkowska, K., Peyruchaud, O., Mikulčić, N., Antolić, M., Shah, P., Cheasty, A., Tagliavini, A., Nizzardo, A., Pergher, M., Ziviani, L., Milleri, S., Pickering, C., Lahn, M., van der Veen, L., Di Conza, G., Johnson, Z.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10205783/
https://www.ncbi.nlm.nih.gov/pubmed/37234285
http://dx.doi.org/10.1016/j.iotech.2023.100384

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10205783/
https://www.ncbi.nlm.nih.gov/pubmed/37234285
http://dx.doi.org/10.1016/j.iotech.2023.100384

Ejemplares similares